Our Technology
Velocity Sciences Provides the Universal Tool-Kit for Proteomics
High-Performance Aptamers Applications
Detection of PTMs and protein isoforms
HPAs are discovered using proprietary in vitro selection methods that can be tuned to hit the desired target vs. unwanted targets with high similarities
Therapeutic delivery to specific cells
Create drug-HPA conjugates for specific cell targeting and internalization
Highly multiplexed protein detection
Detect hundreds of molecular markers simultaneously with high specificity
Protein detection in sandwich formats
HPAs conform to your detection platform of choice, either in sandwich formats or on beads with MS detection
Proprietary Core Technology
Covering the Next Generation in Molecular Recognition Technology.
We have created an extensive IP portfolio including proprietary methods that cover the next generation in molecular recognition technology to target proteins, peptides, and small molecules. We have captured advances based upon decades of experience and incorporated them into a high-throughput production system. We are producing thousands of new target capture reagents a year, easily functionalized to work on multiple platforms and in many applications.
The Ultimate in Versatility
From decades of research and experience, Velocity has engineered novel modified RNA constructs (High-Performing Aptamers, “HPAs”) that afford increased shape and charge diversity over DNA, which leads to higher affinity/specificity in binding molecular targets, whether proteins, peptides or small molecules. The versatility of our HPAs allows us to work on many different detection platforms.
Exceptional Binders
These HPAs are highly selective and sensitive with structural and enzymatic stability. They can be functionalized with dyes, oligonucleotide barcodes, nanoparticles, and other reagents and deployed across different applications. This enables the use of HPAs for both revealing biological insights and translating those insights across platforms for further research or diagnostics.
Binders to any Target
Our proprietary in-vitro selection methods are optimized for stringency, higher affinity, and improved specificity, and have been refined over thousands of selections. Our use of next-generation sequencing (NGS) and proprietary artificial intelligence enables us to identify unique candidates that can be designed for specific purposes (for example, targeting specific post-translational modifications or splice variants.)
Proprietary Molecules Make the Difference
Our novel nucleobase modifications provide enhanced success in finding multiple quality HPAs to given targets, often binding to multiple unique epitopes, enabling more specific targeting.
Scale to Meet Any Need
Our proprietary chemistries and methods have been reduced to repeatable practices and been automated, enabling us to scale the production of HPAs that can be easily functionalized for specific platforms and deployed in small plex or highly multiplex arrays.